Published on
January 7, 2020
- 12:00 GMT
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in ...
Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 Safety profile of pegcetacoplan was comparable to eculizumab in …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
